{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:14:01Z","timestamp":1783638841669,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02288-7","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:34:58Z","timestamp":1778870098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation"],"prefix":"10.1186","volume":"28","author":[{"given":"Weijia","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"4","key":"2288_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"issue":"12","key":"2288_CR2","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1080\/09603123.2025.2492826","volume":"35","author":"NA Elhawary","year":"2025","unstructured":"Elhawary NA, et al. Descriptive epidemiology of female breast cancer around the world: incidence, mortality, and sociodemographic risks and disparities. Int J Environ Health Res. 2025;35(12):3648\u201362.","journal-title":"Int J Environ Health Res"},{"issue":"4","key":"2288_CR3","doi-asserted-by":"publisher","first-page":"100087","DOI":"10.1016\/j.modpat.2022.100087","volume":"36","author":"X Baez-Navarro","year":"2023","unstructured":"Baez-Navarro X, et al. HER2-Low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort. Mod Pathol. 2023;36(4):100087.","journal-title":"Mod Pathol"},{"issue":"8","key":"2288_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"R Bradley","year":"2021","unstructured":"Bradley R, et al. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2288_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","volume":"20","author":"S Loi","year":"2019","unstructured":"Loi S, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial. Lancet Oncol. 2019;20(3):371\u201382.","journal-title":"Lancet Oncol"},{"key":"2288_CR6","doi-asserted-by":"publisher","first-page":"175883591983351","DOI":"10.1177\/1758835919833519","volume":"11","author":"S Pernas","year":"2019","unstructured":"Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Therapeutic Adv Med Oncol. 2019;11:1758835919833519.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"2288_CR7","doi-asserted-by":"publisher","first-page":"216747","DOI":"10.1016\/j.canlet.2024.216747","volume":"588","author":"J Sun","year":"2024","unstructured":"Sun J, et al. CD63\u2009+\u2009cancer-associated fibroblasts confer CDK4\/6 inhibitor resistance to breast cancer cells by exosomal miR-20. Cancer Lett. 2024;588:216747.","journal-title":"Cancer Lett"},{"issue":"1","key":"2288_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-024-02106-8","volume":"23","author":"Z Lin","year":"2024","unstructured":"Lin Z, et al. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications. Mol Cancer. 2024;23(1):191.","journal-title":"Mol Cancer"},{"issue":"6","key":"2288_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/cancers14061519","volume":"14","author":"P De","year":"2022","unstructured":"De P, et al. B\u00eate noire of chemotherapy and targeted therapy: CAF-mediated resistance. Cancers. 2022;14(6):1519.","journal-title":"Cancers"},{"issue":"2","key":"2288_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cancers13020318","volume":"13","author":"R Zeng","year":"2021","unstructured":"Zeng R, Dong J. The hippo signaling pathway in drug resistance in cancer. Cancers. 2021;13(2):318.","journal-title":"Cancers"},{"issue":"9","key":"2288_CR11","first-page":"1611","volume":"128","author":"J Luo","year":"2023","unstructured":"Luo J, et al. The oncogenic roles and clinical implications of YAP\/TAZ in breast cancer. Br J Cancer. 2023;128(9):1611\u201324.","journal-title":"Br J Cancer"},{"key":"2288_CR12","doi-asserted-by":"crossref","unstructured":"Wang W et al. YAP\/TAZ Pathway promoted the trastuzumab resistance in HER2-positive breast cancer. Pakistan J Zool, 2023;55(5):2391.","DOI":"10.17582\/journal.pjz\/20220630020601"},{"key":"2288_CR13","doi-asserted-by":"crossref","unstructured":"Gonzalez-Alonso P et al. The hippo pathway transducers YAP1\/TEAD induce acquired resistance to trastuzumab in HER2-positive breast cancer. Cancers (Basel). 2020;12(5):1108.","DOI":"10.3390\/cancers12051108"},{"issue":"6","key":"2288_CR14","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1021\/acsnano.4c11630","volume":"19","author":"X Luo","year":"2025","unstructured":"Luo X, McAndrews KM, Kalluri R. Natural and bioengineered extracellular vesicles in diagnosis, monitoring and treatment of cancer. ACS Nano. 2025;19(6):5871\u201396.","journal-title":"ACS Nano"},{"issue":"4","key":"2288_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/15548627.2019.1635381","volume":"16","author":"H Peng","year":"2020","unstructured":"Peng H, et al. The ubiquitin-specific protease USP8 directly deubiquitinates SQSTM1\/p62 to suppress its autophagic activity. Autophagy. 2020;16(4):698\u2013708.","journal-title":"Autophagy"},{"issue":"9","key":"2288_CR16","first-page":"4411","volume":"12","author":"M Musielak","year":"2022","unstructured":"Musielak M, et al. Biological heterogeneity of primary cancer-associated fibroblasts determines the breast cancer microenvironment. Am J Cancer Res. 2022;12(9):4411\u201327.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2288_CR17","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1096\/fj.201701561RRRR","volume":"33","author":"Y Li","year":"2019","unstructured":"Li Y, et al. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell\u2010like properties. FASEB J. 2019;33(4):4851\u201365.","journal-title":"FASEB J"},{"issue":"35","key":"2288_CR18","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1038\/s41388-022-02415-6","volume":"41","author":"Y Gu","year":"2022","unstructured":"Gu Y, et al. TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer. Oncogene. 2022;41(35):4119\u201329.","journal-title":"Oncogene"},{"key":"2288_CR19","doi-asserted-by":"crossref","unstructured":"Yang M et al. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. J Clin Investig. 2023;133(14).","DOI":"10.1172\/JCI164428"},{"issue":"9","key":"2288_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41419-022-05240-7","volume":"13","author":"P Yang","year":"2022","unstructured":"Yang P, et al. CAF-derived exosomal WEE2-AS1 facilitates colorectal cancer progression via promoting degradation of MOB1A to inhibit the Hippo pathway. Cell Death Dis. 2022;13(9):796.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2288_CR21","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.3390\/cancers12113253","volume":"12","author":"K Kaushal","year":"2020","unstructured":"Kaushal K, Ramakrishna S. Deubiquitinating enzyme-mediated signaling networks in cancer stem cells. Cancers. 2020;12(11):3253.","journal-title":"Cancers"},{"key":"2288_CR22","unstructured":"Szyma\u0144ska M. Endocytic downregulation of the oncoproteins ErbB2 and ErbB3. 2016."},{"issue":"8","key":"2288_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2174\/1568009617666170623123848","volume":"18","author":"D Sanchala","year":"2018","unstructured":"Sanchala D, Bhatt LK, Prabhavalkar KS. Therapeutic approaches for the treatment of epidermal growth factor receptor mutated lung cancer. Curr Cancer Drug Targets. 2018;18(8):773\u201391.","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"2288_CR24","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3390\/ijms25094620","volume":"25","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Biological roles and clinical applications of exosomes in breast cancer: a brief review. Int J Mol Sci. 2024;25(9):4620.","journal-title":"Int J Mol Sci"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02288-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:22:19Z","timestamp":1783635739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02288-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2288"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02288-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Ethics Committee of Wujin Hospital Affiliated with Jiangsu University (Approval No. 2025-SR-422). All procedures were conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines. All animal experiments were approved by the Laboratory Animal Ethics Committee of Guangdong Medical Laboratory Animal Center (Approval No. D202502-7) and were conducted in accordance with national guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}